China Drug Approvals Up 26%, Mostly Due To Generics
This article was originally published in PharmAsia News
Executive SummaryChina's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
You may also be interested in...
China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.
China Pharma Innovation Hinges On Participation Of Medical Experts – SFDA Drug Registration Director
China approves less than 10 new chemical entities annually, according to SFDA Director of Drug Registration Wei Zhang, who has urged healthcare professionals to join China’s innovation efforts.
China hopes strengthened communication with sponsors will spur innovation and new drug approvals.